Posted in Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study April 16, 2026 Pharmaceutical Technology Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs. Clinical DataOncologyRead full story